SLC6A2
ENSG00000103546
Target class
Transporter
Chromosome
16
Approved drugs
62
Clinical candidates (approved and in development)
77
- Approved drugs
- 62
- Clinical candidates (approved and in development)
- 77
- Chemical probe available
- Yes
- Other names
- NET
- Target name
- SLC6A2
- Gene name
- Solute carrier family 6 member 2
- Gene symbol
- SLC6A2
- Protein name
- Sodium-dependent noradrenaline transporter (Norepinephrine transporter) (NET) (Solute carrier family 6 member 2)
- NET1
- NAT1
- SLC6A5
- Gene biotype
- Protein coding
- Gene family
- Solute carrier family 6
- Target class
- Transporter
- Target type
- Human gene
- Tissues expressed in
- 2
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 6.57
- Tissue specificity (Gini)
- 0.815
- Tissue specificity (tau)
- 0.975
- KEGG gene identifiers
- hsa:6530
- Protein interaction confidence
- 0.791563
- Protein interaction partners
- 16
- R-HSA-442660
- R-HSA-5619109
- End position
- 55707645
- Start position
- 55655988
- Chromosome
- 16
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein . Cell projection, axon . Synapse, synaptosome .
- Cytosol
- Mitochondria
Publication evidence
- PubMed 11343649
- Tissue specificity (tau)
- 0.974843
- Expression inequality (Gini)
- 0.815334
Expression in transcripts per million
- Testis
- 6.57
- Skin - Not Sun Exposed (Suprapubic)
- 1.54
- Skin - Sun Exposed (Lower leg)
- 0.91
- Adipose - Subcutaneous
- 0.72
- Breast - Mammary Tissue
- 0.72
Expression in transcripts per million
- Testis6.57
- Skin - Not Sun Exposed (Suprapubic)1.54
- Skin - Sun Exposed (Lower leg)0.91
- Adipose - Subcutaneous0.72
- Breast - Mammary Tissue0.72
- Esophagus - Gastroesophageal Junction0.59
- Uterus0.47
- Esophagus - Muscularis0.45
- Adipose - Visceral (Omentum)0.37
- Cervix - Endocervix0.37
- Cervix - Ectocervix0.29
- Adrenal Gland0.26
- Fallopian Tube0.23
- Vagina0.21
- Nerve - Tibial0.2
- Prostate0.16
- Minor Salivary Gland0.16
- Bladder0.16
- Small Intestine - Terminal Ileum0.1
- Kidney - Cortex0.09
- Kidney - Medulla0.09
- Ovary0.08
- Esophagus - Mucosa0.08
- Colon - Sigmoid0.08
- Artery - Coronary0.06
And 29 more, listed on the interactive page.
- GO:0006836
- GO:0007268
- GO:0051620
- GO:0070050
- GO:0005886
- GO:0016020
- GO:0003779
- GO:0005330
- GO:0005334
- GO:0005515
- GO:0008504
ventricular hypertrophy
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: ventricular hypertrophy
- nervous system
- cardiovascular
PubMed 28216264increased heart rate
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased heart rate
- nervous system
- cardiovascular
PubMed 28216264constipation
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: constipation
- nervous system
- cardiovascular
PubMed 28216264decreased locomotor activity
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased locomotor activity
- nervous system
- cardiovascular
PubMed 28216264orthostatic hypotension
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: orthostatic hypotension
- nervous system
- cardiovascular
PubMed 28216264drug abuse/dependence
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: drug abuse/dependence
- nervous system
- cardiovascular
PubMed 28216264decreased pain
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased pain
- nervous system
- cardiovascular
PubMed 28216264tachycardia
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: tachycardia
Biological samples
- cardiovascular system
Evidence sourceincreased blood pressure
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased blood pressure
- nervous system
- cardiovascular
PubMed 28216264increased QTc interval
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased QTc interval
- nervous system
- cardiovascular
PubMed 28216264hypertension (supine)
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: hypertension (supine)
Biological samples
- cardiovascular system
Evidence sourcedecreased salivation
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased salivation
- nervous system
- cardiovascular
PubMed 28216264decreased sleep
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased sleep
- nervous system
- cardiovascular
PubMed 28216264sweating
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: sweating
- nervous system
- cardiovascular
PubMed 28216264blurred vision
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: blurred vision
- nervous system
- cardiovascular
PubMed 28216264increased cardiac output
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased cardiac output
- nervous system
- cardiovascular
PubMed 28216264decreased pupillary reflex
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased pupillary reflex
- nervous system
- cardiovascular
PubMed 28216264decreased eating
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased eating
- nervous system
- cardiovascular
PubMed 28216264congestive heart failure
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: congestive heart failure
Biological samples
- cardiovascular system
Evidence sourceurinary hesitancy
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: urinary hesitancy
- nervous system
- cardiovascular
PubMed 28216264
increased locomotor activity
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: increased locomotor activity
- cardiovascular system
- central nervous system
PubMed 23197038constipation
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: constipation
- cardiovascular system
- central nervous system
PubMed 23197038receptor binding
Studies
- biochemical: NVS_TR_hNET, is one of one assay component(s) measured or calculated from the NVS_TR_hNET assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.
Biological samples
- cell-free
Evidence sourceincreased blood pressure
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: increased blood pressure
- cardiovascular system
- central nervous system
PubMed 23197038abuse potential
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: abuse potential
- cardiovascular system
- central nervous system
PubMed 23197038increased heart rate
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: increased heart rate
- cardiovascular system
- central nervous system
PubMed 23197038
Related records
Trials (2,254)
- 'Fix the Dysfunction' Concept for Mechanism-based Pharmacological Treatment of Neuropathic Pain by Drug
- "MILNACIPRAN" in Subjects With Chronic Shoulder Pain
- [C-11]NPA PET-amphetamine in Cocaine Use Disorders
- 12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder
- 124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study
- 131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol
- 131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol
- 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma
- 131I-MIBG With Myeloablative Chemotherapy and Autologous Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma
- 131MIBG to Treat Malignant Pheochromocytoma
- 48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO)
- 6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder
- 8 Week Multi-site Study of MYDAYIS® for Bipolar Depression
- A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD
- A 52-Week Study of Bicifadine in Patients With Chronic Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
- A 6-week Study to Evaluate the Safety and Efficacy of Quillichew ERCT in 4-5 Year Old Children With ADHD.
- A Bioequivalence (BE) Study in Healthy Subjects
- A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD
- A Brain Imaging Study Into Nicotine Induced Dopamine Release in Cigarette Smokers.
- A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)
Drugs (112)
- Amitifadine Monoamine transporter inhibitor
- Amitriptyline Norepinephrine transporter inhibitor
- Amitriptyline hydrochloride Norepinephrine transporter inhibitor
- Amoxapine Norepinephrine transporter inhibitor
- Amphetamine Norepinephrine transporter releasing agent
- Amphetamine adipate Norepinephrine transporter releasing agent
- Amphetamine aspartate Norepinephrine transporter releasing agent
- Amphetamine sulfate Norepinephrine transporter releasing agent
- Ampreloxetine Norepinephrine transporter inhibitor
- Atomoxetine Norepinephrine transporter inhibitor
- Atomoxetine hydrochloride Norepinephrine transporter inhibitor
- Benzphetamine Norepinephrine transporter releasing agent
- Benzphetamine hydrochloride Norepinephrine transporter releasing agent
- Bethanidine Norepinephrine transporter substrate
- Bethanidine sulfate Norepinephrine transporter substrate
- Bicifadine Monoamine transporter inhibitor
- Bretylium Norepinephrine transporter substrate
- Bretylium tosylate Norepinephrine transporter substrate
- Bupropion Norepinephrine transporter inhibitor
- Bupropion hydrobromide Norepinephrine transporter inhibitor